25 September 2026
Novo pitches its post-Wegovy future while Eli Lilly keeps pulling ahead in obesity drugs
Novo Nordisk laid out a long-term plan to replace Wegovy and Ozempic sales, but investors were unimpressed as Eli Lilly grew its share of the obesity market.
Novo Nordisk invented the modern weight-loss drug boom with Wegovy and Ozempic. This week it tried to explain what comes after them. Investors mostly shrugged, and its American rival Eli Lilly kept widening its lead.
What happened
At an investor event on Monday, Novo said it aims to launch more than five potential multi-blockbuster drugs by 2030 (a blockbuster is a drug with $1 billion or more in yearly sales) and to reach about $23 billion of sales from new pipeline drugs by 2035. It expects revenue growth from 2026 to 2030 in line with other big drugmakers, not the breakneck growth of the Wegovy years. The stock fell sharply.
The pressure is simple. Novo's patent on semaglutide, the active ingredient in both drugs, runs until 2032 in key markets. Together they made about $31 billion in 2025, roughly two-thirds of Novo's sales, and cheaper copies can arrive once protection ends.
Lilly, meanwhile, is gaining. It said it held about 61% of the US market for GLP-1 drugs (the hormone-mimicking class that includes all of these medicines) in the second quarter, against about 39% for Novo. CEO Dave Ricks told CNBC that 700,000 seniors have started these drugs since Medicare began covering them in July, and 70% are on Lilly's products. One-third of new patients on GLP-1 pills are taking Lilly's pill, Foundayo, which launched months after Novo's Wegovy pill.
Novo says its Wegovy pill has already reached 7 million US prescriptions, and CEO Mike Doustdar argues the market is big enough for volume to matter as much as share.
Why it matters
Weight-loss drugs are one of the largest new markets in medicine, and the two companies' paths have split. Over the past year Lilly's stock returned about 66% and Novo's US-listed shares lost about 28%, according to Noorult data. At about $1.06 trillion, Lilly is now one of the most valuable companies in the US market.
The fight is also about what comes next. Lilly plans to seek approval for retatrutide, a drug that targets three gut hormones, in early 2027. Novo is counting on CagriSema, a combination drug due early next year, whose past trial results disappointed investors. New data this week looked better, though that study used lower doses of both drugs.
What to watch
- The CagriSema launch early next year and how doctors take to it.
- Whether Foundayo keeps gaining share of the pill market.
- Lilly's retatrutide filing in the first quarter of 2027.
The companies in this story
Based on reporting by CNBC: Novo obesity strategy as Eli Lilly extends lead. Facts, not advice.
More news
- Anthropic's IPO, in numbers: 825 million shares at $70 to $78, and a $1.4 trillion price tag
- Trump says the Nvidia scandal didn't endanger US security, and stands by Lutnick
- Nvidia's first earnings without Huang: what Kress will be asked on Tuesday
- Buffett gives away $5.5 billion of Berkshire stock in his Thanksgiving letter
- Banks are using AI to trim back offices. Proof that it adds revenue is harder to find
- IMF chief says the world economy leans too hard on AI as circular deals top $1 trillion